Patients at risk of sudden cardiac death (SCD) after myocardial infarction (MI) can be offered therapy with implantable cardioverter defibrillators (ICDs). Whether plasma biomarkers can help risk stratify for SCD and ventricular arrhythmias (VT/VF) is unclear.
Introduction
Several clinical trials have shown that implantable cardioverter defibrillators (ICDs) are effective means for the prevention of sudden cardiac death (SCD) in both ischaemic and non-ischaemic patients. 1 -6 However, despite current evidence-based guidelines, ICDs still remain underused or misused, with implantation rates varying from country to country. 7 -9 Notably, patients with ischaemic heart disease and low left ventricular ejection fraction (LVEF) are exposed to an increased risk of SCD 10 and although international guidelines were updated, years ago, to include this population into a Class IA indication for ICD implantation, 11 criticisms still remain. In particular, whether or not all patients with a previous myocardial infarction (MI) and low LVEF should receive an ICD 12 -15 still remains an issue prompting debate and attempts are being made to better risk stratify these patients. Although re-entry mechanisms have been considered the primary cause of ventricular arrhythmias in post-MI patients, recent findings support the hypothesis that acute ischaemia might also represent a prevalent mechanism of sudden death in post-MI, through different mechanisms, from increased release of cytokines, changes in metabolic and ions substrate to inhomogeneous conduction delays and blocks that may also, in turn, facilitate re-entry. 16 -19 The hypothesis behind the study was that different mechanisms underlay the genesis of arrhythmias in these patients and that acute ischaemia may play a dominant role in the occurrence of SCD or in the most fast and life-threatening forms of ventricular arrhythmias [i.e. ventricular fibrillation (VF) or fast ventricular tachycardia (VT)], while re-entry could be mainly associated to slower arrhythmias. Recently, specific plasma biomarkers have been introduced for risk stratification of acute coronary events (e.g. inflammatory cytokines, biomarkers of plaque destabilization and rupture, biomarkers of myocardial stretch). 20 Therefore, the aim of the CAMI-GUIDE (C-reactive protein Assessment post Myocardial Infarction to GUIde DEfibrillator implantation) study was to prospectively test the hypothesis that plasma levels of the prototypic inflammatory biomarker C-reactive protein were associated with the risk of potentially fatal arrhythmias and SCD in a population of ischaemic patients with previous MI and LVEF ,30% who received an ICD according to the inclusion criteria of the MADIT II study. 3 Additionally, NT-proBNP and cystatin-C were also assessed in order to evaluate the potential additive benefit of a multi-marker approach for risk stratification.
Methods
CAMI-GUIDE was a multicentre prospective observational study involving 24 Italian centres experienced in ICD implantation and follow-up. Patients were enrolled between 15 October 2004 and 7 June 2006. The study design, including details on selection criteria, study endpoints, clinical follow-up and sample size, have been previously published. 21 Briefly, the study enrolled patients with a previous MI (.30 days) and LVEF ≤30%, who were candidates for the implantation of an ICD or cardiac resynchronization therapy device with a defibrillator (CRT-D). The primary endpoint was to assess the relationship between C-reactive protein levels recorded at baseline and a combined endpoint of SCD or the occurrence of fast VT (.200 b.p.m.) or VF requiring ICD interventions at 2 years of followup. In particular, the sample was selected to detect an increase in at least 48.6% in the primary outcome in the subgroup of patients with C-reactive protein .3mg/L compared with those with C-reactive protein ≤3 mg/L. Secondary endpoints included all-cause mortality, heart failure (HF) hospitalizations, and HF-related mortality according to baseline C-reactive protein values. In addition to C-reactive protein, NT-proBNP and cystatin-C values were assessed in a parallel analysis to determine the additive prognostic value of a multi-marker approach for determining the risk of SCD or fast VT/VF and of all-cause mortality.
Statistical analysis
Descriptive statistics are presented for all collected variables, overall and according to pre-specified C-reactive protein groups. To evaluate the potential benefit of a multivariable approach for risk stratification, including both serum biomarkers and baseline clinical parameters, a multivariable Cox model was used to analyse the predictive value for all-cause mortality including the three considered biomarkers (PCR; Cys-C; NT-Pro BNP) and those clinical variables collected in the study, significantly linked at univariate analysis or of clinical interest and not collinear. Backward stepwise selection (P to remove .0.1) was performed to obtain a parsimonious model for risk stratification. This was performed by categorizing the predictor index (the linear combination of the predictors in the model) into the tertiles of its distribution. The Harrell's c-statistic for discrimination was computed. Stata 11 (StataCorp, College Station, TX, USA) was used for computation. All tests were two-sided and a P-value , 0.05 was considered statistically significant.
Results

Patient characteristics
A total of 300 patients were recruited during the study. Sixteen patients were excluded from analysis for inclusion criteria violations: PTCA or CABG within 1 or 3 months from implant, respectively (6 patients), LVEF .30% assessed at baseline echocardiogram (five patients), acute MI within 1 month from implant (five patients). One additional patient was excluded for ICD implant refusal after having signed the informed consent. Fifteen patients did not have baseline blood samples drawn and were excluded from the analysis. Finally, 268 patients were considered for the final analysis, which exceeded the predefined minimum number of patients (252) needed to achieve adequate statistical power. 21 One hundred twenty-two patients were implanted with a singlechamber ICD, 51 with dual-chamber ICD, and 94 with a CRT device. One patient was implanted with a dual chamber pacemaker instead of a CRT device due to refusal to ICD after CRT implant failure due to adverse coronary sinus anatomy. According to intention to treat analysis, the patient was included into the data set. One hundred forty-four patients (52.2%) had C-reactive protein at enrolment .3 mg/L. The baseline characteristics of the patients included in the data set ( Table 1) were not statistically different between groups according to C-reactive protein≤3 or .3 mg/L, with the exception of NYHA class and resting HR, that were higher in the C-reactive protein .3 mg/L group.
Events during follow-up and C-reactive protein
Patients were followed for a median of 24 months. During the course of the study 15 patients discontinued the follow-up or withdrew from the study. Two patients who withdrew at the enrolment time were not considered for survival analysis.
Sixty patients (22.6%) died during the follow-up period: the primary endpoint was reached in 46 patients (17.3%), including 10 (3.8%) with SCD and 36 (13.5%), with fast VT/VF. Twenty-one patients (8.3%) died due to HF-related causes; overall, 42 (15.8%) patients died for cardiac causes and 18 for non-cardiac causes (6.8%). No association between C-reactive protein levels (.3 vs. ≤3 mg/L) and the primary endpoint was found following univariate analysis [HR ¼ 0.897 (0.503-1.599) Table 2 ]. Correspondingly, the associated Kaplan-Meier curves were almost superimposed ( Figure 1) . Consistent results were obtained when considering separately each component of the primary endpoint. Similarly, no association with the primary endpoint was evident neither when C-reactive protein was categorized into quartiles nor when it was assessed on a continuous scale (after logtransformation). C-reactive protein levels were associated with allcause mortality, death due to HF and first hospitalization for HF ( Figure 2) . The multivariate analysis for competing risks confirmed that the risk of sudden death or ventricular arrhythmias associated with C-reactive protein was close to the null value, while C-reactive protein had a strong association with HF-related mortality ( Table 3) . Patients with C-reactive protein .3mg/L had a greater than three-fold increase in risk of dying from HF than those with C-reactive protein ≤3 mg/L; this risk remained essentially unchanged after adjusting for covariates in a multivariable analysis [HR: 3.09 (1.37-6.97); P ¼ 0.006). When including the three biomarkers and the baseline clinical variables in a multivariable model, in order to assess their independent prognostic role on all-cause mortality, both C-reactive protein (.3 mg/L) and NT-proBNP (above median) together with NYHA class .II and HR .70 (among clinical parameters) showed a significant association with mortality (Table 4) , C-reactive protein (above median) though marginally non-significant, and associated with a 1.7-fold increase in risk. Cystatin-C was removed from the model. The risk function for all-cause mortality including those biochemical and clinical variables, when divided in tertiles, showed a high discriminating power (Harrell's c ¼ 0.78), eliciting a 2-year morality rate below of 5% in the low risk group vs. a value equal to 50% in the high risk group (Figure 3) . Moreover, if biomarkers were excluded from the model, discrimination dropped (c-statistic ¼ 0.72).
Multi-marker analysis
Discussion
Despite several trials demonstrating the efficacy of ICDs in reducing sudden and all-cause mortality in ischaemic and non-ischaemic patients 1 -6 and the fact that international guidelines have been updated accordingly, ICDs are still underused in clinical practice among different geographies. 7 -9 Implantable cardioverter defibrillator eligibility is commonly debated, particularly when only LVEF is used in the selection of ICD candidates. The limited sensitivity of the LVEF to predict risk of sudden death, as stressed by Buxton et al., 13 may be due to the complex and, probably, incompletely understood pathophysiology of life-threatening arrhythmias. Presently, there is still a lack of validated criteria for additional selection for prophylactic ICD therapy among patients with reduced LVEF; the recent focus on both clinical and noninvasive ECG risk predictors such as QRS duration, T-waves alternans, HR turbulence, and QT variability failed to produce clinically relevant information to date. 15, 25, 26 In this study, we tested the hypothesis that biological markers associated with acute ischaemia or plaque instability may be associated with the mechanisms of SCD or life-threatening ventricular arrhythmias. We focused primarily on high sensitivity C-reactive protein, and, additionally, on a multi-marker approach to investigate risk stratification in post-MI patients with depressed ventricular function.
C-reactive protein, an acute-phase protein associated with inflammatory disorders, has been significantly correlated in ischaemic patients with infarct extension, complications and poor outcome. 27, 28 Elevated levels of C-reactive protein have been demonstrated to be highly predictive of the risk of death in patients with ischaemic heart disease 29 -31 and in apparently healthy subjects. 32 In particular, elevated C-reactive protein levels turned Prediction of ICD intervention by CRP out to be associated with sudden coronary death due to plaque rupture and with the risk of future sudden death in healthy subjects. 29, 30 The CAMI-GUIDE study for the first time tested prospectively the hypothesis that high sensitivity C-reactive protein may play a role in sudden death in patients with previous MI and severely depressed LVEF and may represent a guide for additional risk stratification in patients indicated for ICD implantation according to current guidelines. This study failed to demonstrate an association between C-reactive protein, either on a discrete (quartiles, binomial) or continuous scale, and the occurrence of a composite endpoint of SCD or threatening ventricular arrhythmias and, therefore, to validate C-reactive protein as a marker of risk in these patients. With a hazard ratio close to 1, this study provides no evidence of possible associations between C-reactive protein levels before ICD implantation and future appropriate therapy delivery or SCD. However, the clinical design of the CAMI-GUIDE study, with C-reactive protein levels assessed at ICD implantation Hazard ratio with 95% confidence interval (estimates adjusted for Cystatin-C, NTproBNP, LVEF, heart rate, NYHA, QRS width, diabetes, previous revascularization, dilated post-ischaemic aetiology, peripheral artery disease, history of stroke, and current smoker).
. Hazard ratio with 95% confidence interval. Backward stepwise selection original variables: C-reactive protein, Cystatin-C, NT-Pro BNP, LVEF, resting heart rate, NYHA class, QRS duration, diabetes, previous revascularization, dilated post-ischaemic aetiology, peripheral artery disease, history of stroke, and current smoker. Removed variables with P ≥ 0.1: diabetes, LVEF, QRS duration, previous revascularization, NYHA class, cystatin-C, peripheral artery disease, current smoker. NYHA, New York Heart Association.
and events occurring up to 2 years post-implant, does not allow us to completely exclude the hypothesis that a rise in C-reactive protein during follow-up might have anticipated the occurrence of life-threatening arrhythmias in our population. Therefore, we cannot completely rule out a role of C-reactive protein and inflammation in SCD of ischaemic patients. The absence of any association between C-reactive protein and ventricular arrhythmias in this sample, apparently in contrast with other results obtained in previous studies, 33 -36 may be explained by differences in the enrolled population. C-reactive protein has been shown to be elevated in subjects studied at autopsy after sudden coronary death in association with plaque rupture 29 and in healthy subjects at risk of future sudden death; 30 however, these studies included populations with a low cardiovascular risk. Conversely, the CAMI-GUIDE study involved patients with a higher risk profile, having previous infarction, low ejection fraction and, in several cases, HF. It might be therefore possible that C-reactive protein may emerge as a marker of SCD in low risk population, but that the risk conferred by C-reactive protein is completely blunted in the presence of stronger factors as those present in our population. Additionally, the mechanisms associated to SCD and ventricular arrhythmias may be different: Burke 29 found high levels of C-reactive protein in the blood and plaque of patients died suddenly for a coronary plaque rupture, while in our study the occurrence of new ischaemic events was definitely low. This suggests that plaque rupture and acute ischaemia, conditions that C-reactive protein may be able to detect, were not the major cause of VT/VF occurrence in our patients and that re-entry mechanism was dominant cause for the events. Although this conclusion may appear obvious, it is an important confirmatory observation, as several authors have stressed the possibility that different ischaemia-associated electrophysiological mechanisms may induce TV and FV. 16 -19 To increase sensitivity of our analysis for ischaemic life threatening arrhythmias, we had selected as endpoints FV and fast VT, i.e. those with a HR .200, that are supposed to have a significant ischaemic component. The results from the CAMI-GUIDE study outline the complexity in matter of predicting major ventricular arrhythmias, probably reflecting a poor understanding of their mechanisms in this population, where left ventricular dysfunction, myocardial ischaemia, scar, and sympathetic hyperactivity may all play a different role in each patient. Conversely, a more recent analysis of the MADIT II study analysing 8 year outcomes, 37 showed that ICD implantation based exclusively on low ejection fraction is more efficient in terms of patients needed to treat to save one life than originally thought. Therefore debates for additional risk stratification could be mitigated when taking into account the long-term outcomes of these patients and published guidelines recommending ICD implantation for patients with low ejection fraction could be reinforced.
On the other hand, in this study C-reactive protein was found to be a strong predictor of death for HF and of re-hospitalization for HF, endpoints that have been previously analysed retrospectively or in single-centre studies. 38 -40 The observation that C-reactive protein levels predict HF mortality and re-hospitalization is intriguing: despite resulting from a secondary analysis, this finding suggests a role of inflammation in the pathophysiology of HF. Additionally, this result supports the use of C-reactive protein as a marker of HF risk and underlines the potential adjunctive role of a CRT implant in post-MI patients candidates for an ICD with Figure 3 Kaplan -Meier survival curves for all-cause mortality according to the tertiles of the risk function, calculated from the multivariable model. The upper tertile represents high-risk patients having increased, CRP, NT-Pro BNP, dilated post-ischaemic aetiology, previous stroke, and higher resting HR. BNP, brain natriuretic peptide; HR, heart rate; CRP, C-reactive protein; NYHA, New York Heart Association.
Prediction of ICD intervention by CRP elevated C-reactive protein, in order to prevent disease progression. As a matter of fact, more recently, the MADIT-CRT 41 and REVERSE 42 trials demonstrated the effectiveness of CRT in those patients who were previously indicated only for an ICD.
Multiple biomarkers assessment
NT-proBNP and Cystatin-C were measured to evaluate the potential additive benefit of a multi-marker approach for risk stratification in these patients. Cystatin-C is a marker of renal function, more accurate than creatinine and glomerular filtration rate, which is an excellent marker of death in ischaemic patients. 43, 44 NT-proBNP is the amino terminal part of BNP, a natriuretic peptide that has been consistently shown to be an excellent marker of HF and, in small, recent studies, of sudden death/VT/ VF in ICD recipients. 45 -48 Results of this further analysis provide evidence that NT-proBNP is not only a significant predictor of death for HF, but it is also a predictor of VT/VF and sudden death. The complex pathogenesis of the major ventricular arrhythmias in highrisk post-MI patients might explain why NT-proBNP, which is an accurate marker of LV dysfunction, neuro-hormonal activation, and inflammation, is a predictor of life-threatening arrhythmias and sudden death. 45 The relatively short duration of follow-up might explain why renal function, assessed by Cystatin-C levels, does not predict the outcome in this study (although an almost two-fold increase in risk of dying from any cause was shown). The independent association of biomarkers with all-cause mortality, together with resting HR .70 b.p.m., dilated post-ischaemic aetiology and previous stroke, led to a further improvement of risk stratification that may be of clinical interest. Indeed, it allows identifying subjects with markedly different risk profiles within an apparently homogeneous population of post-MI patients with depressed ventricular function. These findings outline the multifacet nature of cardiac death in post-MI patients with low LVEF in whom no single risk factor can cover all clinical and pathophysiological aspects and stress the importance of a multi-marker approach. 49, 50 The present study has inherent limitations that include the absence of randomization and the fact that the composite endpoint can be considered only a surrogate of SCD, as VT/VF episodes treated by the device cannot be considered equivalent to SCD. However, while closing the doors to pre-implant C-reactive protein as a prognostic marker of sudden death in this population, this study showed that a multi-marker approach, used together with traditional clinical predictors of death (such as HR and NYHA class) results in a better risk stratification of these patients. Therefore, these findings open the possibility to identify subsets with different risk profiles and may help physicians to optimize the management of available resources when treating ischaemic patients indicated for an ICD.
